F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
| Autor: | Martin J. Slater, Graham Edward Morris Sibley, Jason David Oliver, Laura McEntee, Nathan P. Wiederhold, Nicola Beckmann, Katharine S. Dobb, Michael Bromley, Anthony J. Kennedy, Joanne Livermore, Saskia du Pré, William W. Hope, Mike Birch, Derek Law |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Drug chemistry.chemical_classification Aspergillus Multidisciplinary biology media_common.quotation_subject 030106 microbiology Antifungal drug Pharmacology Biological Sciences biology.organism_classification Aspergillus fumigatus Microbiology 03 medical and health sciences chemistry Mechanism of action In vivo Dihydroorotate dehydrogenase medicine Azole medicine.symptom media_common |
| Zdroj: | Oliver, J D, Sibley, G E M, Beckmann, N, Dobb, K S, Slater, M J, McEntee, L, Du Pre, S, Livermore, J, Bromley, M, Wiederhold, N P, Hope, W W, Kennedy, A J, Law, D & Birch, M 2016, ' F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase ', Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 45, pp. 12809–12814 . https://doi.org/10.1073/pnas.1608304113 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA |
| DOI: | 10.1073/pnas.1608304113 |
| Popis: | There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 µg/mL-greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|